Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
3 institutional releases
Published in New England Journal of Medicine · View the paper (DOI)
Researchers found a significant reduction in nosebleed severity, fewer transfusions, and improved quality of life in patients with hereditary hemorrhagic telangiectasia treated with pomalidomide. The trial's results offer hope for people with this rare bleeding disorder.
Coverage from 3 institutions
- Bone marrow cancer drug shows success in treatment of rare blood disorder NIH/National Heart, Lung and Blood Institute · Sep 18, 2024 · first to report
- Cleveland Clinic study is first to show success in treating rare blood disorder Cleveland Clinic · Sep 18, 2024
- Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder Mass General Brigham · Sep 18, 2024